{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:55:10Z","timestamp":1781502910810,"version":"3.54.1"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gynecologic malignancies \u2014 principally cervical cancer (CC), endometrial carcinoma (EC), and ovarian cancer (OC) \u2014 have been managed with conventional modalities including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, yielding modest overall outcomes. The scarcity of effective later-line options has fueled rapid advances in antibody-drug conjugate (ADC) research. Precision-targeted, highly potent ADCs hold the promise of improving outcomes for patients with gynecologic tumors. To date, multiple ADCs directed against antigens such as tissue factor (TF), human epidermal growth factor receptor 2 (HER2), trophoblast cell-surface antigen 2 (Trop2), and folate receptor alpha (FR\u03b1) have entered clinical trials or received regulatory approval for CC, EC, and OC. These agents have demonstrated superiority over conventional chemotherapy in patients with recurrent or metastatic disease, with particularly pronounced efficacy in populations exhibiting high target expression. Nevertheless, clinical translation remains challenged by response heterogeneity attributable to tumor heterogeneity, the emergence of resistance mechanisms, and class-specific adverse events including ocular toxicity, interstitial lung disease (ILD), hepatotoxicity, and peripheral neuropathy. Continued refinement of next-generation ADC platforms \u2014 encompassing bispecific ADCs, dual-payload ADCs, peptide-drug conjugates (PDCs), and radionuclide-conjugated drugs \u2014 is anticipated to overcome current limitations and deliver superior oncologic outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1831465","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:33:58Z","timestamp":1781501638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody-drug conjugates in gynecologic malignancies: breakthroughs, challenges, and future directions"],"prefix":"10.3389","volume":"17","author":[{"given":"Yue","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Gynecology, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of VIP In-Patient Ward, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.967633","article-title":"PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155510","article-title":"Antibody-drug conjugates: The new frontier of chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab vedotin: A review in CD30-positive Hodgkin lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: Mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Research: BCR"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189374","article-title":"The VEGF\/VEGFR2 system in ovarian cancer: From functional to pharmacological significance","volume":"1880","author":"Grillo","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.687926","article-title":"Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency","volume":"12","author":"Su","year":"2021","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: A key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ph14050442","article-title":"The chemistry behind ADCs","volume":"14","author":"Kostova","year":"2021","journal-title":"Pharm (Basel Switzerland)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1021\/acsmedchemlett.6b00274","article-title":"Design, synthesis, and cytotoxic evaluation of novel tubulysin analogues as ADC payloads","volume":"7","author":"Leverett","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193293","article-title":"A comprehensive review of the antitumor properties and mechanistic insights of duocarmycin analogs","volume":"16","author":"Morcos","year":"2024","journal-title":"Cancers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2436-0","article-title":"Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo","volume":"143","author":"Ma","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-024-03727-0","article-title":"Transforming toxins into treatments: The revolutionary role of \u03b1-amanitin in cancer therapy","volume":"98","author":"Ning","year":"2024","journal-title":"Arch Toxicol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-25-0108","article-title":"Targeted delivery of a potent STING agonist payload via an antibody-drug conjugate drives robust antitumor activity in preclinical models","volume":"25","author":"Gruber","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"B24","first-page":"118019","article-title":"Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapy","volume-title":"Eur J Med Chem","author":"Xi","year":"2025"},{"key":"B25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00720","article-title":"Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: Results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study","volume":"41","author":"Vergote","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B27","first-page":"5528","article-title":"Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r\/mCC): Interim results of RC48-C018","volume-title":"J Clin Oncol","author":"Yuan","year":"2024"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1200\/JCO.2025.43.16_suppl.5612","article-title":"SHR-A1811 in patients with HER2-expressing advanced gynecological cancers: A phase 2 study","volume":"43","author":"Kong","year":"2025","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1699","DOI":"10.1002\/cnr2.1699","article-title":"Systematic study of tissue factor expression in solid tumors","volume":"6","author":"de Bono","year":"2023","journal-title":"Cancer Rep (Hoboken, N.J.)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B31","volume-title":"NCCN clinical practice guidelines in oncology: cervical cancer. Version 1.2025","year":"2025"},{"key":"B32","first-page":"3002","article-title":"Phase I\/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors","volume-title":"J Clin Oncol","author":"Park","year":"2024"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-0002","article-title":"Preclinical characterization of XB002, an anti-tissue factor antibody-drug conjugate for the treatment of solid tumors","volume":"24","author":"Kantak","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04204-w","article-title":"Comprehensive advances in HER2-positive and HER2-negative breast cancer: Unveiling molecular mechanisms and exploring cutting-edge targeted therapies for enhanced patient outcomes","volume":"398","author":"Sood","year":"2025","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4172\/2157-2518.S7-003","article-title":"Regulation of apoptosis by HER2 in breast cancer","volume":"2013","author":"Carpenter","year":"2013","journal-title":"J Carcinogenesis Mutagenesis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S307324","article-title":"Spotlight on trastuzumab deruxtecan (DS-8201,T-DXd) for HER2 mutation positive non-small cell lung cancer","volume":"12","author":"Azar","year":"2021","journal-title":"Lung Cancer (Auckland NZ)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0057","article-title":"Cervical cancer, version 2.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: A novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Delivery"},{"key":"B40","doi-asserted-by":"crossref","first-page":"S720","DOI":"10.1016\/j.annonc.2025.08.1801","article-title":"1165P Cadonilimab in combination with disitamab vedotin or nab-paclitaxel in the treatment of recurrent or metastatic cervical cancer: A prospective, double-cohort, multi-center, open-label, phase II clinical study (AK001)","volume":"36","author":"Zheng","year":"2025","journal-title":"Ann Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02044","article-title":"Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2-directed antibody-drug conjugate, in human epidermal growth factor receptor 2-expressing or mutated advanced solid tumors: A global phase I trial","volume":"42","author":"Yao","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 antibody-drug conjugates in solid tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu Rev Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061744","article-title":"Overview of Trop-2 in cancer: From pre-clinical studies to future directions in clinical settings","volume":"15","author":"Lombardi","year":"2023","journal-title":"Cancers"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"crossref","first-page":"e70417","DOI":"10.1002\/cncr.70417","article-title":"Antibody\u2013drug conjugates in gynecologic cancers","volume":"132","author":"Barquin","year":"2026","journal-title":"Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"B47","article-title":"1168P Efficacy and safety of sacituzumab tirumotecan (Sac-TMT) monotherapy in advanced\/metastatic cervical cancer: Results from a phase I\/II study (MK-2870-001\/KL264-01)","volume-title":"Annals of oncology","author":"Wang","year":"2025"},{"key":"B48","article-title":"ClinicalTrials.gov identifier: NCT06459180","year":""},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1485461","article-title":"Anti-mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer","volume":"15","author":"Kutle","year":"2024","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","article-title":"Axl in cancer: a modulator of drug resistance and therapeutic target","volume":"42","author":"Tang","year":"2023","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1038\/s41598-017-05977-8","article-title":"Blockade of Axl signaling ameliorates HPV16E6-mediated tumorigenecity of cervical cancer","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00979-4","article-title":"Expression of B7 family checkpoint proteins in cervical cancer","volume":"35","author":"Zong","year":"2022","journal-title":"Modern Pathol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B56","doi-asserted-by":"crossref","first-page":"S550","DOI":"10.1016\/j.annonc.2024.08.781","article-title":"A phase I\/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer","volume":"35","author":"Lee","year":"2024","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): The STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B60","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.776","article-title":"Datopotamab deruxtecan (Dato-DXd) in patients with endometrial or ovarian cancer: Results from the phase II TROPION-PanTumor03 study","volume-title":"Ann Oncol","author":"Oaknin","year":"2024"},{"key":"B61","doi-asserted-by":"publisher","first-page":"A9","DOI":"10.1136\/ijgc-2023-esgo.14","article-title":"DB-1303, a HER2-targeting ADC, for patients with advanced\/metastatic endometrial cancer: preliminary clinical results from an ongoing phase 1\/2a trial (NCT05150691)","volume":"33","author":"Moore","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.3390\/cancers15164085","article-title":"HER2 oncogene as molecular target in uterine serous carcinoma and uterine carcinosarcoma","volume":"15","author":"McNamara","year":"2023","journal-title":"Cancers"},{"key":"B63","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1016\/j.annonc.2024.08.777","article-title":"Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"key":"B64","year":""},{"key":"B65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-025-01686-2","article-title":"Mirvetuximab soravtansine: current and future applications","volume":"18","author":"Kong","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-020-00823-1","article-title":"Co-expression of mesothelin and CA125 is associated with the poor prognosis of endometrial serous carcinoma and mixed carcinomas including serous carcinoma","volume":"26","author":"Kakimoto","year":"2020","journal-title":"Pathol Oncol Res POR"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01131-6","article-title":"Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma","volume":"35","author":"Chen","year":"2022","journal-title":"Modern Pathol"},{"key":"B68","year":""},{"key":"B69","year":""},{"key":"B70","year":""},{"key":"B71","year":""},{"key":"B72","year":""},{"key":"B73","volume-title":"NCCN clinical practice guidelines in oncology: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer. Version 3.2025","year":"2025"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Sci (New York NY)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105206","article-title":"77MO R-DXd monotherapy in patients (pts) with heavily pretreated platinum-sensitive ovarian cancer (PSOC): subgroup analysis of a phase I study","volume":"10","author":"Moore","year":"2025","journal-title":"ESMO Open"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun (London England)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to antibody-drug conjugates","volume":"78","author":"Garc\u00eda-Alonso","year":"2018","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1610","article-title":"SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm","volume":"75","author":"Hamblett","year":"2015","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3546","article-title":"Antibody-maytansinoid conjugates designed to bypass multidrug resistance","volume":"70","author":"Kovtun","year":"2010","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0108-9","article-title":"Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2\/xL in HER2-positive breast cancer","volume":"37","author":"Saatci","year":"2018","journal-title":"Oncogene"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030670","article-title":"The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1","volume":"12","author":"Nadal-Serrano","year":"2020","journal-title":"Cancers"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-drug conjugates: Future directions in clinical and translational strategies to improve the therapeutic index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: From discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov"},{"key":"B99","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/1878-0261.12791","article-title":"Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients","volume":"15","author":"Charo","year":"2021","journal-title":"Mol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831465\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:34:01Z","timestamp":1781501641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831465\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":99,"alternative-id":["10.3389\/fimmu.2026.1831465"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1831465","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"1831465"}}